Skip to main content
. 2020 Jul 21;5(10):1700–1705. doi: 10.1016/j.ekir.2020.07.011

Figure 1.

Figure 1

Patient flow and acute kidney injury (AKI) outcomes among patients treated with programmed death ligand-1 (PD-L1) inhibitors. Overall, 17% of the included cohort developed AKI. ∗Among patients with transient AKI (lasting <48 hours), 36 (53%) occurred in outpatients; the majority did not have creatinine measurements immediately repeated, but it normalized by the following clinic visit (mean: 14 days, SD: 9 days until next check). Among those with AKI that was confirmed to have been sustained AKI, lasting for >48 hours, the etiology and Kidney Disease: Improving Global Outcomes (KDIGO) severity stage are shown. ∗∗Of the 9 patients with KDIGO grade 3 AKI, 4 patients had progressive kidney failure and died during the hospital stay, and none underwent renal replacement therapy. ATN, acute tubular necrosis; SCr, serum creatinine.